Belite Bio (BLTE) Scheduled to Post Earnings on Tuesday

Belite Bio (NASDAQ:BLTE) will release its earnings data after the market closes on Tuesday, November 12th. Analysts expect Belite Bio to post earnings of ($0.30) per share for the quarter.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Price Performance

NASDAQ BLTE traded down $0.59 on Wednesday, reaching $69.51. The company had a trading volume of 5,321 shares, compared to its average volume of 51,952. The firm has a market capitalization of $2.13 billion, a PE ratio of -56.99 and a beta of -1.60. The firm has a 50-day moving average of $53.51 and a 200-day moving average of $49.00. Belite Bio has a 1 year low of $31.00 and a 1 year high of $70.90.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BLTE shares. Benchmark reaffirmed a “buy” rating and set a $57.00 price target on shares of Belite Bio in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Belite Bio in a research report on Thursday, September 12th.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.